Increased serum levels of tissue inhibitor of metalloproteinase-1 in patients with acute myocardial infarction

International Heart Journal

Volumn 50, Issue 4, 2009, Pages 421-431

  Dinh, Wilfried ^a,b   Füth, Reiner ^a,b   Scheffold, Thomas ^b   Bansemir, Lars ^a,b   Köhler, Till ^a   Lapp, Harald ^c   Bufe, Alexander ^a   Nickl, Werner ^a,b   Stasch, Johannes Peter ^d   Lankisch, Mark ^a,b  

^a Helios Clinics Wuppertal   (Germany)

^b UNIVERSITY OF WITTEN HERDECKE   (Germany)

^c HELIOS KLINIKUM ERFURT   (Germany)

^d Cardiovascular Research   (Germany)

Author keywords

Acute myocardial infarction; Biomarkers; Extracellular matrix; Remodeling; TIMP 1

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATINE KINASE; CREATINE KINASE MB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; BIOLOGICAL MARKER;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENZYME BLOOD LEVEL; EXTRACELLULAR MATRIX; FAMILY HISTORY; FEMALE; HEART ATRIUM FIBRILLATION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK FACTOR; SINUS RHYTHM; SMOKING; TRANSLUMINAL CORONARY ANGIOPLASTY; BLOOD; CASE CONTROL STUDY; COHORT ANALYSIS; ENZYMOLOGY; HEART INFARCTION; HEART STROKE VOLUME; MIDDLE AGED; PHYSIOLOGY; TIME;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; CREATINE KINASE, MB FORM; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; STROKE VOLUME; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VENTRICULAR REMODELING;

EID: 70349261208     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.50.421     Document Type: Article

References (40)

1. Robinson TF, Cohen-Gould L, Remily RM, Capasso JM, Factor SM. Extracellular structures in heart muscle. Adv Myocardiol 1985; 5: 243-55.
2. Erlebacher JA, Weiss JL, Weisfeldt ML, Bulkley BH. Early dilation of the infarcted segment in acute transmural myocardial infarction: role of infarct expansion in acute left ventricular enlargement. J Am Coll Cardiol 1984; 4: 201-8.
3. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69: 562-73.
4. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990; 81: 1161-72. (Review)
5. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000; 101: 2981-8. (Review)
6. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999; 79: 215-62. (Review)
7. Pinet F, Beseme O, Cieniewski-Bernard C, et al. Predicting left ventricular remodeling after a first myocardial infarction by plasma proteome analysis. Proteomics 2008; 8: 1798-808.
8. Krzemiński TF, Nozyński JK, Grzyb J, Porc M. Wide-spread myocardial remodeling after acute myocardial infarction in rat. Features for heart failure progression. Vascul Pharmacol 2008; 48: 100-8.
9. Weber KT. Monitoring tissue repair and fibrosis from a distance. Circulation 1997; 96: 2488-92. (Review)
10. Klappacher G, Franzen P, Haab D, et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol 1995; 75: 913-8.
11. Jordán A, Roldán V, García M, et al. Matrix metalloproteinase-1 and its inhibitor, TIMP-1, in systolic heart failure: relation to functional data and prognosis. J Intern Med 2007; 262: 385-92.
12. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 1997; 378: 151-60. (Review)
13. Takahashi S, Barry AC, Factor SM. Collagen degradation in ischaemic rat hearts. Biochem J 1990; 265: 233-41.
14. Gunja-Smith Z, Morales AR, Romanelli R, Woessner JF Jr. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Role of metalloproteinases and pyridinoline cross-links. Am J Pathol 1996; 148: 1639-48.
15. Janicki JS, Brower GL, Henegar JR, Wang L. Ventricular remodeling in heart failure: the role of myocardial collagen. Adv Exp Med Biol 1995; 382: 239-45. (Review)
16. Spinale FG, Coker ML, Thomas CV, Walker JD, Mukherje R, Hebber L. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res 1998; 82: 482-95.
17. Coker ML, Thomas CV, Clair MJ, et al. Myocardial matrix metalloproteinase activity and abundance with congestive heart failure. Am J Physiol 1998; 274: H1516-23.
18. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ 3rd, Spinale FG. Increased matrix metalloproteinase activity and selective regulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 1998; 97: 1708-15.
19. Elmas E, Lang S, Erik Dempfle CE et al. High plasma levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) and interieukin-8 (IL-8) characterize patients prone to ventricular fibrillation complicating myocardial infarction. Clin Chem Lab Med 2007; 45: 1360-5.
20. Vanhoutte D, Schellings M, Pinto Y, Heymans S. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc Res 2006; 69: 604-13. (Review)
21. Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 2001; 141: 211-7.
22. Hirohata S, Kusachi S, Murakami M, et al. Time dependent alterations of serum matrix metalloproteinase-1 and metalloproteinase-1 tissue inhibitor after successful reperfusion of acute myocardial infarction. Heart 1997; 78: 278-84.
23. Beltrami CA, Finato N, Rocco M, et al. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation 1994; 89: 151-63.
24. Cleutjens JP, Kandala JC, Guarda E, Guntaka RV, Weber KT. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol 1995; 27: 1281-92.
25. Dollery CM, McEwan JR. Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995; 77: 863-8. (Review)
26. Rouleau JL, de Champlain J, Klein M, et al. Activation of neurohumoral systems in postinfarction left ventricular dysfunction. J Am Coll Cardiol 1993; 22: 390-8.
27. Ikonomidis JS, Hendrick JW, Parkhurst AM, et al. Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition. Am J Physiol Heart Circ Physiol 2005; 288: H149-58.
28. Trescher K, Bernecker O, Fellner B, et al. Inflammation and postinfarct remodeling: overexpression of IkappaB prevents ventricular dilation via increasing TIMP levels. Cardiovasc Res 2006; 69: 746-54.
29. Uusimaa P, Risteli J, Niemelä M, et al. Collagen scar formation after acute myocardial infarction: relationships to infarct size, left ventricular function, and coronary artery patency. Circulation 1997; 96: 2565-72.
30. Cavusoglu E, Ruwende C, Chopra V, et al. Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction. Am Heart J 2006; 151: 1101. e1-8.
31. Lubos E, Schnabel R, Rupprecht HJ, et al. Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: results from the AtheroGene study. Eur Heart J 2006; 27: 150-6.
32. Kelly D, Khan SQ, Thompson M, et al. Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. Eur Heart J 2008.
33. Sato Y, Kataoka K, Matsumori A, et al. Measuring serum aminoterminal type III procollagen peptide, 7S domain of type IV collagen, and cardiac troponin T in patients with idiopathic dilated cardiomyopathy and secondary cardiomyopathy. Heart 1997; 78: 505-8.
34. Spinale FG, Coker ML, Krombach SR, et al. Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. Circ Res 1999; 85: 364-76.
35. McElmurray JH 3rd, Mukherjee R, New RB, et al. Angiotensin-converting enzyme and matrix metalloproteinase inhibition with developing heart failure: comparative effects on left ventricular function and geometry. J Pharmacol Exp Ther 1999; 291: 799-811.
36. Zhang X, Yang YJ, Zhu WL, Huang Y, Zhu ZM. [Effects of angiotensin II receptor antagonism on matrix metalloproteinases and fibronectin in rats with experimental myocardial infarction]. Zhonghua Xin Xue Guan Bing Za Zhi 2006; 34: 1029-34. (Chinese)
37. Rohde LE, Ducharme A, Arroyo LH, et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 1999; 99: 3063-70.
38. Herskowitz A, Choi S, Ansari AA, Wesselingh S. Cytokine mRNA expression in postischemic/reperfused myocardium. Am J Pathol 1995; 146: 419-28.
39. Latini R, Bianchi M, Correale E, et al. Cytokines in acute myocardial infarction: selective increase in circulating tumor necrosis factor, its soluble receptor, and interleukin-1 receptor antagonist. J Cardiovasc Pharmacol 1994; 23: 1-6.
40. Elmas E, Lang S, Dempfle CE, et al. High plasma levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) and interleukin-8 (IL-8) characterize patients prone to ventricular fibrillation complicating myocardial infarction. Clin Chem Lab Med 2007; 45: 1360-5.